Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches

Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental illnesses. Prescribing information typically focuses on how to initiate treatment from the corresponding oral formulations. However, in clinical prac...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on pharmacotherapy Vol. 24; no. 13; p. 1463
Main Authors Højlund, Mikkel, Correll, Christoph U
Format Journal Article
LanguageEnglish
Published England 02.09.2023
Subjects
Online AccessGet more information

Cover

Loading…
Abstract Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental illnesses. Prescribing information typically focuses on how to initiate treatment from the corresponding oral formulations. However, in clinical practice other scenarios, such as switching from other oral antipsychotics or other LAIs, occur frequently, requiring guidance. Pharmacodynamic properties of antipsychotics and their relation to rebound symptoms. Pharmacokinetic properties of LAIs and their implications for switching approaches. Specific approaches to switching to LAIs. The LAI landscape has evolved significantly in the last decade with more formulations available, longer dosing intervals, and extended indications. However, currently available LAIs have various shortcomings, e.g. short dosing intervals, need for oral supplementation, loading regimens, deep intramuscular injection and/or restricted indications. Recent improvements include a one-day initiation option for aripiprazole lauroxil, aripiprazole monohydrate once-monthly, risperidone in situ microparticles and subcutaneous risperidone. Future LAI developments should focus on longer dosing intervals, subcutaneous administration, expansion of LAIs beyond currently available antipsychotic agents and indications beyond schizophrenia and bipolar disorder. In the future, LAIs might become a first-line treatment after initial oral stabilization for chronic mental disorders with need for maintenance treatment and presence of significant non-adherence.
AbstractList Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental illnesses. Prescribing information typically focuses on how to initiate treatment from the corresponding oral formulations. However, in clinical practice other scenarios, such as switching from other oral antipsychotics or other LAIs, occur frequently, requiring guidance. Pharmacodynamic properties of antipsychotics and their relation to rebound symptoms. Pharmacokinetic properties of LAIs and their implications for switching approaches. Specific approaches to switching to LAIs. The LAI landscape has evolved significantly in the last decade with more formulations available, longer dosing intervals, and extended indications. However, currently available LAIs have various shortcomings, e.g. short dosing intervals, need for oral supplementation, loading regimens, deep intramuscular injection and/or restricted indications. Recent improvements include a one-day initiation option for aripiprazole lauroxil, aripiprazole monohydrate once-monthly, risperidone in situ microparticles and subcutaneous risperidone. Future LAI developments should focus on longer dosing intervals, subcutaneous administration, expansion of LAIs beyond currently available antipsychotic agents and indications beyond schizophrenia and bipolar disorder. In the future, LAIs might become a first-line treatment after initial oral stabilization for chronic mental disorders with need for maintenance treatment and presence of significant non-adherence.
Author Højlund, Mikkel
Correll, Christoph U
Author_xml – sequence: 1
  givenname: Mikkel
  orcidid: 0000-0002-5786-5203
  surname: Højlund
  fullname: Højlund, Mikkel
  organization: Child and Adolescent Mental Health Centre, Mental Health Services Capital Region of Denmark, Copenhagen, Denmark
– sequence: 2
  givenname: Christoph U
  orcidid: 0000-0002-7254-5646
  surname: Correll
  fullname: Correll, Christoph U
  organization: Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37345508$$D View this record in MEDLINE/PubMed
BookMark eNo1T9tKxDAUDKK4F_0EpT_QNc219U0WV4UFH9Tn5TSXbdY2CU1E9u_tojIPM8MMA7NA5z54g9BNhVcVrvFdxQSfIFYEE7oihNSiFmdoXknGSimEmKFFSgeMCW44u0QzKinjHNdz9Pn27bLqnN8XORR98PsSVD5Z5w9GZWh7U4DPLqaj6kJ2Kt0XsYNxABX6sHcK-kIFn5w2I2Q3qamuizieZk4hxDgGUJ1JV-jCQp_M9R8v0cfm8X39XG5fn17WD9tSUSFyaY2VNUhCGwqtZEC5xUYLyakBSxSrqsYaIhQzUnMDXDAplGa6biW20zGyRLe_u_GrHYzexdENMB53_6_JD8PpXcM
CitedBy_id crossref_primary_10_1080_14737175_2024_2325655
ContentType Journal Article
DBID NPM
DOI 10.1080/14656566.2023.2228686
DatabaseName PubMed
DatabaseTitle PubMed
DatabaseTitleList PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1744-7666
ExternalDocumentID 37345508
Genre Journal Article
Review
GroupedDBID ---
00X
03L
0BK
0R~
29G
4.4
53G
5GY
AAMIU
AAOUU
AAPWH
ABBAB
ABEIZ
ABJNI
ABJYH
ABLIJ
ABLKL
ABVAX
ABXYU
ACGFS
ACIEZ
ADCVX
ADRBQ
ADTOD
AECIN
AENEX
AEOZL
AGDLA
AGMLL
AIJEM
AIRBT
AIYSM
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
BABNJ
BLEHA
CAZVN
CCCUG
CKQYL
CS3
DASJU
DAWQK
DKSSO
DU5
EBS
EJD
EMOBN
F5P
H13
HZ~
KRBQP
KSSTO
KUULJ
KWAYT
KYCEM
LJTGL
LSO
M44
M4Z
NPM
O9-
P2P
RNANH
TBQAZ
TDBHL
TERGH
TFDNU
TFL
TFW
TUROJ
TZHSB
V1S
~1N
ID FETCH-LOGICAL-c366t-fef78a72393ab74a35f0ed6753eaf2c4119fe26c4e7d5ea56476cd4d8b70f7342
IngestDate Wed Oct 16 00:38:35 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 13
Keywords haloperidol
olanzapine
risperidone
Antipsychotic
aripiprazole
paliperidone
schizophrenia
fluphenazine
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c366t-fef78a72393ab74a35f0ed6753eaf2c4119fe26c4e7d5ea56476cd4d8b70f7342
ORCID 0000-0002-5786-5203
0000-0002-7254-5646
PMID 37345508
ParticipantIDs pubmed_primary_37345508
PublicationCentury 2000
PublicationDate 2023-09-02
PublicationDateYYYYMMDD 2023-09-02
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-02
  day: 02
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Expert opinion on pharmacotherapy
PublicationTitleAlternate Expert Opin Pharmacother
PublicationYear 2023
SSID ssj0020954
Score 2.420626
SecondaryResourceType review_article
Snippet Long-acting injectable antipsychotics (LAIs) are an effective, but potentially underutilized treatment option in schizophrenia and other severe mental...
SourceID pubmed
SourceType Index Database
StartPage 1463
Title Switching to long-acting injectable antipsychotics: pharmacological considerations and practical approaches
URI https://www.ncbi.nlm.nih.gov/pubmed/37345508
Volume 24
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFLYKkyYuCMaAAZt8QFyKSxs7dsKNVUzVpFVIayVuKE5s1B9LKwhCcOBv5zl2frTqtMEliuLGqfy-PL3nvO97CB1DpiMFjSWBDIUTJoKYhLrtk8j3KdeQc0luiMK_-rw3ZD-v_etG46XOLslkK35eySt5j1XhGtjVsGTfYNlyUrgA52BfOIKF4fhfNv79OMpsLSREkNNZeksMTSEnqZjtlZwVBSs3clQrUxNEL5rzSq3ayYPYnp2uKM4qB-TcKaMj4DTHXanhuKzcU3dZ05Ct8oAzLSfNFlUKeuZD_PdgPH1w3YtHk4kqizq6pjWI_e5Rihw0h_WNCI_mlVbWkyrrPAVjRHDbRaXwrpYhXaCI1nwl-Gi60onbqseOUXKDYLNlntUyG1XcimbXDDv_k1uWCmrI2cG_R5e0tYuhNbQmAuMl-2avx6XrEHyygvMVtM9W_p8N9LGYYykvyeOTwRbadIkFvrAo2UYNlX5CJ1fWLE-neFAR7e5P8Qm-qlDwtIMmJZRwNsM1KOEKSngRSud4CUh4EUjw8wSXQMIVkD6j4Y_LQbdHXB8OElPOM6IVvLSRMGJ5kRQsor5uqwQyTaoi7cWs0wm18njMlEh8FfmcCR4nLAmkaGtYHW8XraezVO0jrKjq-BK8QMBDpjwtIduIQp7E4BrghugL2rOLeDO3Yis3xfIe_HXkEG1UcDxCHzS83eorhIqZ_JZb9BX47mys
link.rule.ids 783
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Switching+to+long-acting+injectable+antipsychotics%3A+pharmacological+considerations+and+practical+approaches&rft.jtitle=Expert+opinion+on+pharmacotherapy&rft.au=H%C3%B8jlund%2C+Mikkel&rft.au=Correll%2C+Christoph+U&rft.date=2023-09-02&rft.eissn=1744-7666&rft.volume=24&rft.issue=13&rft.spage=1463&rft_id=info:doi/10.1080%2F14656566.2023.2228686&rft_id=info%3Apmid%2F37345508&rft_id=info%3Apmid%2F37345508&rft.externalDocID=37345508